Gut microbiota modulate CD8<sup>+</sup> T cell immunity in gastric cancer through Butyrate/GPR109A/HOPXOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study asked whether gut bacteria and their short-chain fatty acids shape gastric cancer, and by what mechanism. Researchers profiled fecal and blood bacteria and short-chain fatty acids in patients and controls. They then used antibiotic-treated mice, fecal transplants, butyrate supplementation, and GPR109A-knockout mice. Finally they tested butyrate on cultured cancer cells, on CD8 T cells, and on CAR-Claudin 18.2 CD8 T cells in vitro and in tumor-bearing mice.
Who was studied?
The human sample was 20 gastric cancer patients and 20 healthy volunteers, aged 30 to 75, providing feces and blood in China. Tumor and adjacent tissue was analyzed from 50 to 60 patient pairs. Mouse work used C57BL/6J mice given H. pylori plus N-methyl-N-nitrosourea to induce cancer, with 10 to 12 animals per group. Cell work used human gastric cancer lines MGC-803, HGC-27, and SNU-216 versus the normal line GES-1.
What were the most important findings?
Gastric cancer patients showed gut dysbiosis with fewer short-chain-fatty-acid-producing genera and markedly lower fecal acetate, butyrate, and total short-chain fatty acids, mirrored in serum. Tumor tissue had reduced GPR109A and GPR43. Mice given patient microbiota developed more gastric tumors and had lower butyrate than mice given healthy microbiota. Butyrate cut cancer-cell proliferation and raised apoptosis via GPR109A and HOPX. In mice, butyrate or a high-fiber diet reduced tumor number and raised IFN-gamma CD8 T cells, effects lost when GPR109A was knocked out. Butyrate at 0.5 mmol/L maximized IFN-gamma and boosted CAR-Claudin 18.2 CD8 T cell killing.
What are the greatest implications of this study?
The findings suggest gut-derived butyrate helps restrain gastric cancer by sharpening CD8 T cell cytotoxicity through the GPR109A and HOPX axis. This points to microbiota or butyrate support as a possible adjunct to immunotherapy. Butyrate also enhanced CAR-Claudin 18.2 CD8 T cell activity, hinting at value for engineered cell therapy. The work is preclinical, using patient samples plus mouse and cell models, so human treatment benefit remains to be tested.